Physician profile
Gregory Ales
NPI 1205825692
$6,577.28
in general payments reported to CMS, 2019-2025
59 companies · $13.62 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $398 · 2021: $1,804 · 2022: $1,653 · 2023: $2,427 · 2024: $44.40 · 2025: $13.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.74 | 2021-2023 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $421.14 | 2019-2025 | |
| Ucb, INC. | $308.07 | 2020-2023 | Nayzilam, Fintepla |
| Merz Pharmaceuticals, LLC | $281.63 | 2021-2023 | Xeomin |
| Alexion Pharmaceuticals, INC. | $269.07 | 2020-2023 | Ultomiris |
| Abbott Laboratories | $259.88 | 2019-2023 | Infinity |
| Biogen, INC. | $247.27 | 2021-2023 | Vumerity, Tysabri |
| Sk Life Science, INC. | $203.88 | 2020-2023 | Xcopri |
| Jazz Pharmaceuticals INC. | $193.28 | 2021-2023 | |
| Acorda Therapeutics, INC | $191.89 | 2021-2023 | Inbrija |
| Lilly USA, LLC | $187.13 | 2019-2023 | Emgality, Reyvow, Amyvid |
| Genzyme Corporation | $183.06 | 2020-2023 | |
| Emd Serono, INC. | $170.55 | 2020-2023 | Mavenclad |
| Eisai INC. | $170.30 | 2020-2023 | |
| Acadia Pharmaceuticals INC | $159.04 | 2019-2023 | Nuplazid, Daybue |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.